KIT and neoplasm: Apatinib is a new antitumor angiogenic drug that competitively binds to tyrosine ATP binding sites within VEGFR-2 to interfere with VEGF signaling, and it also inhibits platelet production factor receptor β and c-kit, thereby compromising tumor angiogenesis.